메뉴 건너뛰기




Volumn 7, Issue 5, 2011, Pages 324-326

Why should we define and target early Crohn's disease?

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB;

EID: 79957952568     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note
Times cited : (10)

References (6)
  • 1
    • 77149169736 scopus 로고    scopus 로고
    • Early Crohn disease: A proposed definition for use in disease-modification trials
    • Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut. 2010;59:141-147.
    • (2010) Gut , vol.59 , pp. 141-147
    • Peyrin-Biroulet, L.1    Loftus Jr., E.V.2    Colombel, J.F.3    Sandborn, W.J.4
  • 2
    • 77954423661 scopus 로고    scopus 로고
    • Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: An analysis of PRECiSE 2 randomized maintenance trial data
    • PRECiSE 2 Study Investigators
    • Schreiber S, Colombel JF, Bloomfield R, et al; PRECiSE 2 Study Investigators. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105:1574-1582.
    • (2010) Am J Gastroenterol , vol.105 , pp. 1574-1582
    • Schreiber, S.1    Colombel, J.F.2    Bloomfield, R.3
  • 3
    • 79951696378 scopus 로고    scopus 로고
    • Development of the Crohn's disease digestive damage score, the Lémann score
    • Nov 28. Epub ahead of print
    • Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2010 Nov 28. Epub ahead of print.
    • (2010) Inflamm Bowel Dis
    • Pariente, B.1    Cosnes, J.2    Danese, S.3
  • 4
    • 74049136834 scopus 로고    scopus 로고
    • Disability in inflammatory bowel diseases: Developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health
    • Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis. 2010;16:15-22.
    • (2010) Inflamm Bowel Dis , vol.16 , pp. 15-22
    • Peyrin-Biroulet, L.1    Cieza, A.2    Sandborn, W.J.3
  • 5
    • 39449085441 scopus 로고    scopus 로고
    • Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: An open randomized trial
    • Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club
    • D'Haens G, Baert F, van Assche G, et al; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomized trial. Lancet. 2008;371:660-667.
    • (2008) Lancet , vol.371 , pp. 660-667
    • D'Haens, G.1    Baert, F.2    Van Assche, G.3
  • 6
    • 77950988234 scopus 로고    scopus 로고
    • Infliximab, azathioprine, or combination therapy for Crohn's disease
    • SONIC Study Group
    • Colombel JF, Sandborn WJ, Reinisch W, et al; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
    • (2010) N Engl J Med , vol.362 , pp. 1383-1395
    • Colombel, J.F.1    Sandborn, W.J.2    Reinisch, W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.